| Year |
Citation |
Score |
| 2023 |
Manni A, Sun YW, Schell TD, Lutsiv T, Thompson H, Chen KM, Aliaga C, Zhu J, El-Bayoumy K. Complementarity between Microbiome and Immunity May Account for the Potentiating Effect of Quercetin on the Antitumor Action of Cyclophosphamide in a Triple-Negative Breast Cancer Model. Pharmaceuticals (Basel, Switzerland). 16. PMID 37895893 DOI: 10.3390/ph16101422 |
0.316 |
|
| 2023 |
Jia B, Zhao C, Minagawa K, Shike H, Claxton DF, Ehmann WC, Rybka WB, Mineishi S, Wang M, Schell TD, Prabhu KS, Paulson RF, Zhang Y, Shultz LD, Zheng H. Acute Myeloid Leukemia Causes T Cell Exhaustion and Depletion in a Humanized Graft-versus-Leukemia Model. Journal of Immunology (Baltimore, Md. : 1950). PMID 37712758 DOI: 10.4049/jimmunol.2300111 |
0.372 |
|
| 2023 |
Elcheva IA, Gowda CP, Bogush D, Gornostaeva S, Fakhardo A, Sheth N, Kokolus KM, Sharma A, Dovat S, Uzun Y, Schell TD, Spiegelman VS. IGF2BP family of RNA-binding proteins regulate innate and adaptive immune responses in cancer cells and tumor microenvironment. Frontiers in Immunology. 14: 1224516. PMID 37503349 DOI: 10.3389/fimmu.2023.1224516 |
0.716 |
|
| 2020 |
Hong PP, Zhu J, Drabick JJ, Schell TD. Investigating the impact of medical comorbidities in patients taking beta blockers and treated with immunotherapy for metastatic melanoma. Journal of Clinical Oncology. 38: e15162-e15162. DOI: 10.1200/Jco.2020.38.15_Suppl.E15162 |
0.304 |
|
| 2020 |
Zhao C, Jia B, Jiang Y, Shike H, Claxton DF, Ehmann WC, Schell TD, Cheng H, Liu B, Zheng H. Abstract 874: Adoptive transfer of cytotoxic lymphocytes generated by engineered human dendritic cells for AML treatment Immunology. DOI: 10.1158/1538-7445.Am2020-874 |
0.315 |
|
| 2019 |
Zhao C, Jia B, Wang M, Schell TD, Claxton DF, Ehmann WC, Rybka WB, Mineishi S, Naik S, Songdej N, Sivik JM, Hohl RJ, Zeng H, Zheng H. Multi-dimensional analysis identifies an immune signature predicting response to decitabine treatment in elderly patients with AML. British Journal of Haematology. PMID 31573077 DOI: 10.1111/Bjh.16228 |
0.421 |
|
| 2019 |
Kokolus KM, Haley JS, Koubek EJ, Gowda R, Dinavahi SS, Sharma A, Claxton DF, Helm KF, Drabick JJ, Robertson GP, Neighbors JD, Hohl RJ, Schell TD. Schweinfurthin natural products induce regression of murine melanoma and pair with anti-PD-1 therapy to facilitate durable tumor immunity. Oncoimmunology. 8: e1539614. PMID 30713799 DOI: 10.1080/2162402X.2018.1539614 |
0.75 |
|
| 2019 |
Jia B, Zhao C, Rakszawski KL, Claxton DF, Ehmann WC, Rybka WB, Mineishi S, Wang M, Shike H, Bayerl MG, Sivik JM, Schell TD, Drabick JJ, Hohl RJ, Zheng H. Eomes+T-betlow CD8+ T cells are functionally impaired and are associated with poor clinical outcome in patients with acute myeloid leukemia (AML). Cancer Research. PMID 30709927 DOI: 10.1158/0008-5472.Can-18-3107 |
0.549 |
|
| 2019 |
Poulose J, Wheelden M, Mackley HB, Schmeck C, Zhu J, Pameijer C, Neves RI, Schell T, Mallon C, Drabick JJ. Utility of concurrent immunoradiation for locally advanced and/or medically inoperable melanoma and Merkel cell carcinoma. Journal of Clinical Oncology. 37: e21053-e21053. DOI: 10.1200/Jco.2019.37.15_Suppl.E21053 |
0.361 |
|
| 2019 |
Karelia DN, Haley JS, Schell TD, Hershock D, Zhu J, Jiang C, Lu J, Zhang J. Abstract 4212: A pilot clinical trial to study the effects of Angelica gigas dietary supplement (CognI.Q) on human immune cells (NCT03630328) Cancer Research. 79: 4212-4212. DOI: 10.1158/1538-7445.Am2019-4212 |
0.341 |
|
| 2019 |
Shenoy G, Madhankumar A, Slagle-Webb B, Mrowczynski O, Schell T, Nesterova D, Lee S, Davalos D, Berens M, Lathia J, Barnholtz-Sloan J, Rubin J, Connor J. TMIC-31. IMPACT OF IRON ON MACROPHAGE IMMUNE PHENOTYPE IN THE GLIOBLASTOMA TUMOR MICROENVIRONMENT Neuro-Oncology. 21: vi254-vi254. DOI: 10.1093/Neuonc/Noz175.1065 |
0.39 |
|
| 2018 |
Bazewicz CG, Dinavahi SS, Schell TD, Robertson GP. Aldehyde Dehydrogenase in Regulatory T Cell Development, Immunity and Cancer. Immunology. PMID 30387499 DOI: 10.1111/Imm.13016 |
0.525 |
|
| 2018 |
Haeryfar SMM, Schell TD. PD-1/PD-L1 co-inhibition shapes anticancer T cell immunodominance: facing the consequences of an immunological ménage à trois. Cancer Immunology, Immunotherapy : Cii. PMID 30132082 DOI: 10.1007/S00262-018-2231-Z |
0.411 |
|
| 2018 |
Jia B, Wang L, Claxton DF, Ehmann WC, Rybka WB, Mineishi S, Rizvi S, Shike H, Bayerl M, Schell TD, Hohl RJ, Zheng H. Bone marrow CD8 T cells express high frequency of PD-1 and exhibit reduced anti-leukemia response in newly diagnosed AML patients. Blood Cancer Journal. 8: 34. PMID 29563517 DOI: 10.1038/S41408-018-0069-4 |
0.416 |
|
| 2018 |
Li G, Liu D, Kimchi ET, Kaifi JT, Qi X, Manjunath Y, Liu X, Deering T, Fox T, Rockey DC, Schell TD, Kester M, Avella DM, Staveley-O'Carroll KF. Nanoliposome C6-Ceramide Increases the Anti-tumor Immune Response and Slows Growth of Liver Tumors in Mice. Gastroenterology. PMID 29408569 DOI: 10.1053/J.Gastro.2017.10.050 |
0.436 |
|
| 2018 |
Kokolus KM, Zhang Y, Sivik JM, Schmeck C, Zhu J, Repasky EA, Drabick JJ, Schell TD. Beta blocker use correlates with better overall survival in metastatic melanoma patients and improves the efficacy of immunotherapies in mice. Oncoimmunology. 7: e1405205. PMID 29399407 DOI: 10.1080/2162402X.2017.1405205 |
0.743 |
|
| 2018 |
Ward-Kavanagh LK, Kokolus KM, Cooper TK, Lukacher AE, Schell TD. Combined sublethal irradiation and agonist anti-CD40 enhance donor T cell accumulation and control of autochthonous murine pancreatic tumors. Cancer Immunology, Immunotherapy : Cii. PMID 29332158 DOI: 10.1007/S00262-018-2115-2 |
0.798 |
|
| 2018 |
Wheelden M, Haley J, Schell T, Kokolus KM, Hershock D, Mallon C, Mackley HB, Sivik JM, Drabick JJ. Persistent high levels of circulating effector memory T cells and anti-nuclear antibodies in metastatic melanoma patients who experience durable CRs to immunotherapy after the cessation of treatment. Journal of Clinical Oncology. 36: e21576-e21576. DOI: 10.1200/Jco.2018.36.15_Suppl.E21576 |
0.735 |
|
| 2017 |
Liu D, Li G, Avella DM, Kimchi ET, Kaifi JT, Rubinstein MP, Camp ER, Rockey DC, Schell TD, Staveley-O'Carroll KF. Sunitinib represses regulatory T cells to overcome immunotolerance in a murine model of hepatocellular cancer. Oncoimmunology. 7: e1372079. PMID 29296523 DOI: 10.1080/2162402X.2017.1372079 |
0.536 |
|
| 2017 |
Memarnejadian A, Meilleur CE, Shaler CR, Khazaie K, Bennink JR, Schell TD, Haeryfar SMM. PD-1 Blockade Promotes Epitope Spreading in Anticancer CD8(+) T Cell Responses by Preventing Fratricidal Death of Subdominant Clones To Relieve Immunodomination. Journal of Immunology (Baltimore, Md. : 1950). PMID 28939757 DOI: 10.4049/Jimmunol.1700643 |
0.515 |
|
| 2017 |
Zhu L, Kong Y, Zhang J, Claxton DF, Ehmann WC, Rybka WB, Palmisiano ND, Wang M, Jia B, Bayerl M, Schell TD, Hohl RJ, Zeng H, Zheng H. Blimp-1 impairs T cell function via upregulation of TIGIT and PD-1 in patients with acute myeloid leukemia. Journal of Hematology & Oncology. 10: 124. PMID 28629373 DOI: 10.1186/S13045-017-0486-Z |
0.421 |
|
| 2017 |
Maru S, Jin G, Schell TD, Lukacher AE. TCR stimulation strength is inversely associated with establishment of functional brain-resident memory CD8 T cells during persistent viral infection. Plos Pathogens. 13: e1006318. PMID 28410427 DOI: 10.1371/Journal.Ppat.1006318 |
0.476 |
|
| 2017 |
Jia B, Wang L, Claxton DF, Ehmann WC, Rybka WB, Mineishi S, Shike H, Bayerl M, Schell TD, Hohl RJ, Zheng H. Bone Marrow CD8 T Cells Express High Frequency of PD-1 and Exhibit Reduced Anti-Leukemia Response in AML Patients Blood. 130: 3946-3946. DOI: 10.1182/Blood.V130.Suppl_1.3946.3946 |
0.456 |
|
| 2017 |
Mackley HB, Liu J, Zhu J, Wagner H, Talamo G, Schell TD, Pameijer C, Neves RI, Anderson B, Kokolus KM, Sivik J, Mallon CA, Koller KM, Drabick JJ. Improved infield response rates and overall survival in patients with metastatic melanoma receiving higher biological equivalent doses of radiation with ipilimumab Journal of Radiation Oncology. 6: 215-223. DOI: 10.1007/S13566-017-0305-8 |
0.7 |
|
| 2016 |
Koller KM, Mackley HB, Liu J, Wagner H, Talamo G, Schell TD, Pameijer C, Neves RI, Anderson B, Kokolus KM, Mallon CA, Drabick JJ. Improved Survival and Complete Response Rates in Patients with Advanced Melanoma Treated with Concurrent Ipilimumab and Radiotherapy versus Ipilimumab Alone. Cancer Biology & Therapy. 0. PMID 27905824 DOI: 10.1080/15384047.2016.1264543 |
0.7 |
|
| 2016 |
Koller KM, Wang W, Schell TD, Cozza EM, Kokolus KM, Neves RI, Mackley HB, Pameijer C, Leung A, Anderson B, Mallon CA, Robertson G, Drabick JJ. Malignant melanoma-The cradle of anti-neoplastic immunotherapy. Critical Reviews in Oncology/Hematology. 106: 25-54. PMID 27637351 DOI: 10.1016/J.Critrevonc.2016.04.010 |
0.698 |
|
| 2016 |
Schietinger A, Philip M, Krisnawan VE, Chiu EY, Delrow JJ, Basom RS, Lauer P, Brockstedt DG, Knoblaugh SE, Hämmerling GJ, Schell TD, Garbi N, Greenberg PD. Tumor-Specific T Cell Dysfunction Is a Dynamic Antigen-Driven Differentiation Program Initiated Early during Tumorigenesis. Immunity. PMID 27521269 DOI: 10.1016/J.Immuni.2016.07.011 |
0.552 |
|
| 2016 |
Li G, Liu D, Cooper TK, Kimchi ET, Qi X, Avella DM, Li N, Yang QX, Kester M, Bart Rountree C, Kaifi JT, Cole DJ, Rockey DC, Schell TD, Staveley-O'Carroll KF. Successful Chemoimmunotherapy against Hepatocellular Cancer in a Novel Murine Mode. Journal of Hepatology. PMID 27520877 DOI: 10.1016/J.Jhep.2016.07.044 |
0.306 |
|
| 2016 |
Kong Y, Zhu L, Schell TD, Zhang J, Claxton DF, Ehmann WC, Rybka W, George MR, Zeng H, Zheng H. T-cell Immunoglobulin and ITIM Domain (TIGIT) Associates with CD8+ T cell Exhaustion and Poor Clinical Outcome in AML Patients. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 26763253 DOI: 10.1158/1078-0432.Ccr-15-2626 |
0.479 |
|
| 2016 |
Koller KM, Mackley HB, Wagner H, Talamo G, Schell T, Pameijer C, Neves RI, Anderson B, Kokolus KM, Mallon C, Drabick JJ. Overall survival in patients with metastatic melanoma treated with concurrent ipilimumab and radiotherapy. Journal of Clinical Oncology. 34: 3023-3023. DOI: 10.1200/Jco.2016.34.15_Suppl.3023 |
0.701 |
|
| 2016 |
Althammer S, Steele K, Rebelatto M, Tan TH, Wiestler T, Schmidt G, Higgs B, Li X, Shi L, Jin X, Antal J, Gupta A, Ranade K, Binning G, Bellmunt J, ... ... Schell TD, et al. 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): late breaking abstracts Journal For Immunotherapy of Cancer. 4. DOI: 10.1186/S40425-016-0191-4 |
0.741 |
|
| 2016 |
Liu D, Li G, Cooper T, Kimchi E, Qi X, Li N, Rockey D, Schell T, Staveley-O’Carroll K. Abstract 4004: Development of a successful combination therapy for hepatocellular cancer by targeting Treg and PD-1 Cancer Research. 76: 4004-4004. DOI: 10.1158/1538-7445.Am2016-4004 |
0.455 |
|
| 2015 |
Kong Y, Zhang J, Claxton DF, Ehmann WC, Rybka WB, Zhu L, Zeng H, Schell TD, Zheng H. PD-1(hi)TIM-3(+) T cells associate with and predict leukemia relapse in AML patients post allogeneic stem cell transplantation. Blood Cancer Journal. 5: e330. PMID 26230954 DOI: 10.1038/Bcj.2015.58 |
0.481 |
|
| 2015 |
Wyluda EJ, Cheng J, Schell TD, Haley JS, Mallon C, Neves RI, Robertson G, Sivik J, Mackley H, Talamo G, Drabick JJ. Durable complete responses off all treatment in patients with metastatic malignant melanoma after sequential immunotherapy followed by a finite course of BRAF inhibitor therapy. Cancer Biology & Therapy. 16: 662-70. PMID 25806780 DOI: 10.1080/15384047.2015.1026507 |
0.402 |
|
| 2015 |
Cozza EM, Cooper TK, Budgeon LR, Christensen ND, Schell TD. Protection from tumor recurrence following adoptive immunotherapy varies with host conditioning regimen despite initial regression of autochthonous murine brain tumors. Cancer Immunology, Immunotherapy : Cii. 64: 325-36. PMID 25408469 DOI: 10.1007/S00262-014-1635-7 |
0.589 |
|
| 2015 |
Koller KM, Mackley HB, Wagner H, Neves RI, Schell T, Anderson B, Pameijer C, Mallon C, Drabick JJ. Concurrent ipilimumab and radiotherapy in patients with metastatic melanoma: A retrospective analysis. Journal of Clinical Oncology. 33: e20048-e20048. DOI: 10.1200/Jco.2015.33.15_Suppl.E20048 |
0.456 |
|
| 2015 |
Ward-Kavanagh L, Cooper TK, Lukacher A, Schell TD. Whole body irradiation and agonist anti-CD40 synergize to promote adoptive T cell therapy of resistant murine pancreatic neuroendocrine tumors Journal For Immunotherapy of Cancer. 3: P50. DOI: 10.1186/2051-1426-3-S2-P50 |
0.534 |
|
| 2014 |
Ward-Kavanagh LK, Zhu J, Cooper TK, Schell TD. Whole-body irradiation increases the magnitude and persistence of adoptively transferred T cells associated with tumor regression in a mouse model of prostate cancer. Cancer Immunology Research. 2: 777-88. PMID 24801834 DOI: 10.1158/2326-6066.Cir-13-0164 |
0.532 |
|
| 2014 |
Sagar D, Masih S, Schell T, Jacobson S, Comber JD, Philip R, Wigdahl B, Jain P, Khan ZK. In vivo immunogenicity of Tax(11-19) epitope in HLA-A2/DTR transgenic mice: implication for dendritic cell-based anti-HTLV-1 vaccine. Vaccine. 32: 3274-84. PMID 24739247 DOI: 10.1016/J.Vaccine.2014.03.087 |
0.467 |
|
| 2014 |
Rytelewski M, Meilleur CE, Yekta MA, Szabo PA, Garg N, Schell TD, Jevnikar AM, Sharif S, Singh B, Haeryfar SM. Suppression of immunodominant antitumor and antiviral CD8+ T cell responses by indoleamine 2,3-dioxygenase. Plos One. 9: e90439. PMID 24587363 DOI: 10.1371/Journal.Pone.0090439 |
0.539 |
|
| 2014 |
Sagar D, Masih S, Schell T, Rahman S, Jain P, Khan ZK. Impact of dendritic cells and adjuvant on the in vivo immunogenicity of HTLV-1 Tax 11-19 epitope in hybrid HLA-A2.1/DTR transgenic mice Retrovirology. 11: P72. DOI: 10.1186/1742-4690-11-S1-P72 |
0.422 |
|
| 2013 |
Goodwin EM, Zhong Q, Abendroth CS, Ward-Kavanagh LK, Schell TD, Cooper TK. Anaplastic renal carcinoma expressing SV40 T antigen in a female TRAMP mouse. Comparative Medicine. 63: 338-41. PMID 24209969 |
0.321 |
|
| 2013 |
Ward-Kavanagh LK, Cooper TK, Schell TD. Whole body irradiation combined with adoptive T cell transfer results in regression of high-grade intraepithelial neoplasia and long-term persistence of tumor-specific CD8+ T cells in TRAMP mice Journal For Immunotherapy of Cancer. 1. DOI: 10.1186/2051-1426-1-S1-P37 |
0.508 |
|
| 2013 |
Liu D, Li G, Kimchi ET, Yang QX, Schell T, Staveley-O'Carroll KF. Abstract 4710: Sunitinib prevents tumor-induced immunotolerance in novel murine model of hepatocellular carcinoma (HCC) through modulating CD4+CD25+Foxp3+ regulatory T cells via TGF-β signaling. Cancer Research. 73: 4710-4710. DOI: 10.1158/1538-7445.Am2013-4710 |
0.521 |
|
| 2013 |
Cozza EM, Budgeon LR, Christensen ND, Schell TD. Abstract 3975: Regression of established tumors requires timely adoptive T cell transfer following whole body irradiation. Cancer Research. 73: 3975-3975. DOI: 10.1158/1538-7445.Am2013-3975 |
0.544 |
|
| 2013 |
Ward-Kavanagh L, Cooper T, Schell TD. Abstract 3960: Whole body irradiation extends the duration of antitumor immunity toward established prostate tumors by adoptively transferred CD8+ T cells in TRAMP mice. Cancer Research. 73: 3960-3960. DOI: 10.1158/1538-7445.Am2013-3960 |
0.553 |
|
| 2012 |
Watson AM, Mylin LM, Thompson MM, Schell TD. Modification of a tumor antigen determinant to improve peptide/MHC stability is associated with increased immunogenicity and cross-priming a larger fraction of CD8+ T cells. Journal of Immunology (Baltimore, Md. : 1950). 189: 5549-60. PMID 23175697 DOI: 10.4049/Jimmunol.1102221 |
0.699 |
|
| 2012 |
Clawson GA, Kimchi E, Patrick SD, Xin P, Harouaka R, Zheng S, Berg A, Schell T, Staveley-O'Carroll KF, Neves RI, Mosca PJ, Thiboutot D. Circulating tumor cells in melanoma patients. Plos One. 7: e41052. PMID 22829910 DOI: 10.1371/Journal.Pone.0041052 |
0.408 |
|
| 2012 |
Wilson JJ, Pack CD, Lin E, Frost EL, Albrecht JA, Hadley A, Hofstetter AR, Tevethia SS, Schell TD, Lukacher AE. CD8 T cells recruited early in mouse polyomavirus infection undergo exhaustion. Journal of Immunology (Baltimore, Md. : 1950). 188: 4340-8. PMID 22447978 DOI: 10.4049/Jimmunol.1103727 |
0.449 |
|
| 2012 |
Maleki Varek S, Harding MJ, Waithman J, Zanker D, Shivji AN, Rytelewski M, Mazzuca DM, Yekta MA, Chen W, Schell TD, Haeryfar SMM. Differential regulation of simultaneous antitumor and alloreactive CD8 + T-cell responses in the same host by rapamycin American Journal of Transplantation. 12: 233-239. PMID 22026814 DOI: 10.1111/J.1600-6143.2011.03811.X |
0.531 |
|
| 2012 |
Avella DM, Li G, Schell TD, Liu D, Zhang SS, Lou X, Berg A, Kimchi ET, Tagaram HR, Yang Q, Shereef S, Garcia LS, Kester M, Isom HC, Rountree CB, et al. Regression of established hepatocellular carcinoma is induced by chemoimmunotherapy in an orthotopic murine model. Hepatology (Baltimore, Md.). 55: 141-52. PMID 21898502 DOI: 10.1002/Hep.24652 |
0.467 |
|
| 2011 |
Campbell C, Zhang R, Haley JS, Liu X, Loughran T, Schell TD, Albert R, Thakar J. Why Do CD8+ T Cells become Indifferent to Tumors: A Dynamic Modeling Approach. Frontiers in Physiology. 2: 32. PMID 21808621 DOI: 10.3389/Fphys.2011.00032 |
0.578 |
|
| 2011 |
Manuel SL, Schell TD, Rahman S, Khan ZK, Jain P. Modulation of dendritic cell functions by HTLV-1 with DCs able to direct the presentation of Tax through infected T cells, live virus, and the Tax protein Retrovirology. 8: A103. DOI: 10.1186/1742-4690-8-S1-A103 |
0.503 |
|
| 2011 |
Vareki SM, Harding M, Waithman J, Zanker D, Shivji A, Rytelewski M, Mazzuca D, Yekta M, Chen W, Schell T, Haeryfar SMM. Abstract C225: Differential regulation of simultaneous antitumor and alloreactive CD8+ T cell responses in the same host by rapamycin. Molecular Cancer Therapeutics. 10. DOI: 10.1158/1535-7163.Targ-11-C225 |
0.553 |
|
| 2010 |
Drabick JJ, Schell TD. Poking CD40 for cancer therapy, another example of the Goldilocks effect. Cancer Biology & Therapy. 10: 994-6. PMID 21057206 DOI: 10.4161/Cbt.10.10.13976 |
0.416 |
|
| 2010 |
Fateh S, Schell TD, Gingrich R, Neves RI, Drabick JJ. Unsuccessful high dose IL-2 therapy followed immediately by near continuous low dose temozolomide can result in rapid durable complete and near-complete remissions in metastatic melanoma. Cancer Biology & Therapy. 10: 1091-7. PMID 20930514 DOI: 10.4161/Cbt.10.11.13452 |
0.355 |
|
| 2010 |
Tatum AM, Watson AM, Schell TD. Direct presentation regulates the magnitude of the CD8+ T cell response to cell-associated antigen through prolonged T cell proliferation. Journal of Immunology (Baltimore, Md. : 1950). 185: 2763-72. PMID 20660711 DOI: 10.4049/Jimmunol.0903920 |
0.773 |
|
| 2009 |
Manuel SL, Schell TD, Acheampong E, Rahman S, Khan ZK, Jain P. Presentation of human T cell leukemia virus type 1 (HTLV-1) Tax protein by dendritic cells: the underlying mechanism of HTLV-1-associated neuroinflammatory disease. Journal of Leukocyte Biology. 86: 1205-16. PMID 19656902 DOI: 10.1189/Jlb.0309172 |
0.498 |
|
| 2009 |
Hu J, Schell TD, Peng X, Cladel NM, Balogh KK, Christensen ND. Strong and Specific Protective and Therapeutic Immunity Induced by Single HLA-A2.1 Restricted Epitope DNA Vaccine in Rabbits Procedia in Vaccinology. 1: 4-14. DOI: 10.1016/J.Provac.2009.07.003 |
0.313 |
|
| 2008 |
Ryan CM, Staveley-O'Carroll K, Schell TD. Combined anti-CD40 conditioning and well-timed immunization prolongs CD8+ T cell accumulation and control of established brain tumors. Journal of Immunotherapy (Hagerstown, Md. : 1997). 31: 906-20. PMID 18832997 DOI: 10.1097/Cji.0B013E318189F155 |
0.729 |
|
| 2008 |
Tatum AM, Mylin LM, Bender SJ, Fischer MA, Vigliotti BA, Tevethia MJ, Tevethia SS, Schell TD. CD8+ T cells targeting a single immunodominant epitope are sufficient for elimination of established SV40 T antigen-induced brain tumors. Journal of Immunology (Baltimore, Md. : 1950). 181: 4406-17. PMID 18768900 DOI: 10.4049/Jimmunol.181.6.4406 |
0.699 |
|
| 2008 |
de Witte MA, Bendle GM, van den Boom MD, Coccoris M, Schell TD, Tevethia SS, van Tinteren H, Mesman EM, Song JY, Schumacher TN. TCR gene therapy of spontaneous prostate carcinoma requires in vivo T cell activation. Journal of Immunology (Baltimore, Md. : 1950). 181: 2563-71. PMID 18684947 DOI: 10.4049/Jimmunol.181.4.2563 |
0.509 |
|
| 2008 |
Tagaram HR, Watson AM, Lemonnier FA, Staveley-O'Carroll K, Tevethia SS, Schell TD. An SV40 VP1-derived epitope recognized by CD8+ T cells is naturally processed and presented by HLA-A*0201 and cross-reactive with human polyomavirus determinants. Virology. 376: 183-90. PMID 18402997 DOI: 10.1016/J.Virol.2008.02.033 |
0.653 |
|
| 2008 |
Yorty JL, Tevethia SS, Schell TD. Rapid accumulation of adoptively transferred CD8+ T cells at the tumor site is associated with long-term control of SV40 T antigen-induced tumors. Cancer Immunology, Immunotherapy : Cii. 57: 883-95. PMID 18004562 DOI: 10.1007/S00262-007-0424-Y |
0.596 |
|
| 2007 |
Otahal P, Knowles BB, Tevethia SS, Schell TD. Anti-CD40 conditioning enhances the T(CD8) response to a highly tolerogenic epitope and subsequent immunotherapy of simian virus 40 T antigen-induced pancreatic tumors. Journal of Immunology (Baltimore, Md. : 1950). 179: 6686-95. PMID 17982058 DOI: 10.4049/Jimmunol.179.10.6686 |
0.589 |
|
| 2007 |
Mylin LM, Schell TD, Epler M, Kusuma C, Assis D, Matsko C, Smith A, Allebach A, Tevethia SS. Diversity of escape variant mutations in Simian virus 40 large tumor antigen (SV40 Tag) epitopes selected by cytotoxic T lymphocyte (CTL) clones. Virology. 364: 155-68. PMID 17368499 DOI: 10.1016/J.Virol.2007.02.007 |
0.436 |
|
| 2006 |
Hu J, Peng X, Schell TD, Budgeon LR, Cladel NM, Christensen ND. An HLA-A2.1-transgenic rabbit model to study immunity to papillomavirus infection. Journal of Immunology (Baltimore, Md. : 1950). 177: 8037-45. PMID 17114477 DOI: 10.4049/Jimmunol.177.11.8037 |
0.322 |
|
| 2006 |
Otahal P, Schell TD, Hutchinson SC, Knowles BB, Tevethia SS. Early immunization induces persistent tumor-infiltrating CD8+ T cells against an immunodominant epitope and promotes lifelong control of pancreatic tumor progression in SV40 tumor antigen transgenic mice. Journal of Immunology (Baltimore, Md. : 1950). 177: 3089-99. PMID 16920946 DOI: 10.4049/Jimmunol.177.5.3089 |
0.584 |
|
| 2006 |
Sheil JM, Frankenberry MA, Schell TD, Brundage KM, Barnett JB. Propanil exposure induces delayed but sustained abrogation of cell-mediated immunity through direct interference with cytotoxic T-lymphocyte effectors. Environmental Health Perspectives. 114: 1059-64. PMID 16835059 DOI: 10.1289/Ehp.8774 |
0.452 |
|
| 2006 |
Ryan CM, Schell TD. Accumulation of CD8+ T cells in advanced-stage tumors and delay of disease progression following secondary immunization against an immunorecessive epitope. Journal of Immunology (Baltimore, Md. : 1950). 177: 255-67. PMID 16785521 DOI: 10.4049/Jimmunol.177.1.255 |
0.732 |
|
| 2006 |
Otahal P, Schell T, Bartunkova J, Tevethia S. F.112. CD8+ T-Cell Based Immunotherapy of Pancreatic Insulinomas in Sv40 T Antigen Transgenic Mice Clinical Immunology. 119: S90. DOI: 10.1016/J.Clim.2006.04.152 |
0.501 |
|
| 2005 |
Otahal P, Hutchinson SC, Mylin LM, Tevethia MJ, Tevethia SS, Schell TD. Inefficient cross-presentation limits the CD8+ T cell response to a subdominant tumor antigen epitope. Journal of Immunology (Baltimore, Md. : 1950). 175: 700-12. PMID 16002665 DOI: 10.4049/Jimmunol.175.2.700 |
0.573 |
|
| 2004 |
Barton LF, Runnels HA, Schell TD, Cho Y, Gibbons R, Tevethia SS, Deepe GS, Monaco JJ. Immune defects in 28-kDa proteasome activator gamma-deficient mice. Journal of Immunology (Baltimore, Md. : 1950). 172: 3948-54. PMID 15004203 DOI: 10.4049/Jimmunol.172.6.3948 |
0.413 |
|
| 2004 |
Schell TD. In vivo expansion of the residual tumor antigen-specific CD8+ T lymphocytes that survive negative selection in simian virus 40 T-antigen-transgenic mice. Journal of Virology. 78: 1751-62. PMID 14747540 DOI: 10.1128/Jvi.78.4.1751-1762.2004 |
0.557 |
|
| 2003 |
Stanic AK, Shashidharamurthy R, Bezbradica JS, Matsuki N, Yoshimura Y, Miyake S, Choi EY, Schell TD, Van Kaer L, Tevethia SS, Roopenian DC, Yamamura T, Joyce S. Another view of T cell antigen recognition: cooperative engagement of glycolipid antigens by Va14Ja18 natural T(iNKT) cell receptor [corrected]. Journal of Immunology (Baltimore, Md. : 1950). 171: 4539-51. PMID 14568927 DOI: 10.4049/Jimmunol.171.9.4539 |
0.416 |
|
| 2003 |
Anglen CS, Truckenmiller ME, Schell TD, Bonneau RH. The dual role of CD8+ T lymphocytes in the development of stress-induced herpes simplex encephalitis. Journal of Neuroimmunology. 140: 13-27. PMID 12864968 DOI: 10.1016/S0165-5728(03)00159-0 |
0.479 |
|
| 2003 |
Staveley-O'Carroll K, Schell TD, Jimenez M, Mylin LM, Tevethia MJ, Schoenberger SP, Tevethia SS. In vivo ligation of CD40 enhances priming against the endogenous tumor antigen and promotes CD8+ T cell effector function in SV40 T antigen transgenic mice. Journal of Immunology (Baltimore, Md. : 1950). 171: 697-707. PMID 12847236 DOI: 10.4049/Jimmunol.171.2.697 |
0.585 |
|
| 2003 |
Stanic AK, Shashidharamurthy R, Bezbradica JS, Matsuki N, Yoshimura Y, Miyake S, Choi EY, Schell TD, Van Kaer L, Tevethia SS, Roopoenian DC, Yamamura T, Joyce S. Another View of T Cell Antigen Recognition: Cooperative Engagement of Glycolipid Antigens by Va14Ja18 Natural TCR The Journal of Immunology. 172: 717.2-717. DOI: 10.4049/jimmunol.172.1.717-a |
0.344 |
|
| 2002 |
Schell TD, Mylin LM, Tevethia SS, Joyce S. The assembly of functional beta(2)-microglobulin-free MHC class I molecules that interact with peptides and CD8(+) T lymphocytes. International Immunology. 14: 775-82. PMID 12096037 DOI: 10.1093/Intimm/Dxf041 |
0.345 |
|
| 2001 |
Schell TD, Tevethia SS. Control of advanced choroid plexus tumors in SV40 T antigen transgenic mice following priming of donor CD8+ T lymphocytes by the endogenous tumor antigen1 Journal of Immunology. 167: 6947-6956. PMID 11739514 DOI: 10.4049/Jimmunol.167.12.6947 |
0.579 |
|
| 2001 |
Schell TD, Lippolis JD, Tevethia SS. Cytotoxic T lymphocytes from HLA-A2.1 transgenic mice define a potential human epitope from simian virus 40 large T antigen Cancer Research. 61: 873-879. PMID 11221873 |
0.384 |
|
| 2001 |
Schell TD, Tevethia SS. Cytotoxic T lymphocytes in SV40 infections Methods in Molecular Biology (Clifton, N.J.). 165: 243-256. PMID 11217391 DOI: 10.1385/1-59259-117-5:243 |
0.401 |
|
| 2000 |
Mylin LM, Schell TD, Roberts D, Epler M, Boesteanu A, Collins EJ, Frelinger JA, Joyce S, Tevethia SS. Quantitation of CD8+ T-lymphocyte responses to multiple epitopes from simian virus 40 (SV40) large T antigen in C57BL/6 mice immunized with SV40, SV40 T-antigen-transformed cells, or vaccinia virus recombinants expressing full-length T antigen or epitope minigenes Journal of Virology. 74: 6922-6934. PMID 10888631 DOI: 10.1128/Jvi.74.15.6922-6934.2000 |
0.535 |
|
| 2000 |
Schell TD, Knowles BB, Tevethia SS. Sequential loss of cytotoxic T lymphocyte responses to simian virus 40 large T antigen epitopes in T antigen transgenic mice developing osteosarcomas. Cancer Research. 60: 3002-12. PMID 10850449 |
0.412 |
|
| 1999 |
Schell TD, Mylin LM, Georgoff I, Teresky AK, Levine AJ, Tevethia SS. Cytotoxic T-lymphocyte epitope immunodominance in the control of choroid plexus tumors in simian virus 40 large T antigen transgenic mice. Journal of Virology. 73: 5981-93. PMID 10364350 DOI: 10.1128/Jvi.73.7.5981-5993.1999 |
0.463 |
|
| 1998 |
Fu TM, Mylin LM, Schell TD, Bacik I, Russ G, Yewdell JW, Bennink JR, Tevethia SS. An endoplasmic reticulum-targeting signal sequence enhances the immunogenicity of an immunorecessive simian virus 40 large T antigen cytotoxic T-lymphocyte epitope. Journal of Virology. 72: 1469-81. PMID 9445050 DOI: 10.1128/Jvi.72.2.1469-1481.1998 |
0.341 |
|
| Show low-probability matches. |